Charles River Says Biotech Demand Is Back — Bookings Hit Four-Year High
Charles River (CRL) stock jumped after Q2 earnings beat estimates and the company raised its full-year 2026 guidance.
Share
Why It Matters
Charles River did better than people expected and said the rest of the year will be good too, which means companies making new medicines are buying their testing services again after a slower time.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.